IL122162A - Crystalline form iii atorvastatin and pharmaceutical composition containing it - Google Patents

Crystalline form iii atorvastatin and pharmaceutical composition containing it

Info

Publication number: IL122162A
Authority: IL; Israel
Prior art keywords: pharmaceutical composition; crystalline form; form iii; composition containing; iii atorvastatin
Prior art date: 1995-07-17

Application number

IL12216296A

Other languages

English (en)

Other versions

IL122162A0 (en

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-17

Filing date

1996-07-08

Publication date

1999-07-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL122162(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-08 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1996-07-11 Priority to IL128863A priority Critical patent/IL128863A/en

1998-04-05 Publication of IL122162A0 publication Critical patent/IL122162A0/xx

1999-07-14 Publication of IL122162A publication Critical patent/IL122162A/xx

Links

XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
229960005370 atorvastatin Drugs 0.000 title 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
159000000007 calcium salts Chemical class 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000000634 powder X-ray diffraction Methods 0.000 abstract 1
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

IL12216296A 1995-07-17 1996-07-08 Crystalline form iii atorvastatin and pharmaceutical composition containing it IL122162A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL128863A IL128863A (en)	1995-07-17	1996-07-11	Crystalline form III hydrate of [R * R *) - R)] - 2 - (4 - fluorophenyl) - ß - δ - dihydroxy - 5 - (1 - methylethyl) - 3 - phenyl - 4 - ([phenylamino) carbonyl ] - HI Pyrrole - 1 - Leptic acid hydrochloric acid (autorbastatin)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US145495P	1995-07-17	1995-07-17
PCT/US1996/011367 WO1997003958A1 (en)	1995-07-17	1996-07-08	Form iii crystalline (r-(r,r)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)

Publications (2)

Publication Number	Publication Date
IL122162A0 IL122162A0 (en)	1998-04-05
IL122162A true IL122162A (en)	1999-07-14

Family

ID=21696105

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL12216296A IL122162A (en)	1995-07-17	1996-07-08	Crystalline form iii atorvastatin and pharmaceutical composition containing it
IL128863A IL128863A (en)	1995-07-17	1996-07-11	Crystalline form III hydrate of [R * R *) - R)] - 2 - (4 - fluorophenyl) - ß - δ - dihydroxy - 5 - (1 - methylethyl) - 3 - phenyl - 4 - ([phenylamino) carbonyl ] - HI Pyrrole - 1 - Leptic acid hydrochloric acid (autorbastatin)
IL177378A IL177378A0 (en)	1995-07-17	2006-08-08	Form iii crystalline (r-rr)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methylethyl)3-phenyl-4-(phenylamino)carbonyl)-ih-pyrrole-1-heptanoic acid hemi calcium salt ( atorvastatin)

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL128863A IL128863A (en)	1995-07-17	1996-07-11	Crystalline form III hydrate of [R * R *) - R)] - 2 - (4 - fluorophenyl) - ß - δ - dihydroxy - 5 - (1 - methylethyl) - 3 - phenyl - 4 - ([phenylamino) carbonyl ] - HI Pyrrole - 1 - Leptic acid hydrochloric acid (autorbastatin)
IL177378A IL177378A0 (en)	1995-07-17	2006-08-08	Form iii crystalline (r-rr)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methylethyl)3-phenyl-4-(phenylamino)carbonyl)-ih-pyrrole-1-heptanoic acid hemi calcium salt ( atorvastatin)

Country Status (32)

Country	Link
US (1)	US6121461A (da)
JP (1)	JP3296563B2 (da)
KR (1)	KR100431039B1 (da)
CN (1)	CN1081632C (da)
AT (1)	ATE207465T1 (da)
AU (1)	AU725368B2 (da)
BG (1)	BG63629B1 (da)
BR (1)	BR9610567A (da)
CA (1)	CA2220458C (da)
CO (1)	CO4700442A1 (da)
CZ (1)	CZ294109B6 (da)
DK (1)	DK0848704T3 (da)
EA (1)	EA000505B1 (da)
EE (1)	EE03607B1 (da)
ES (1)	ES2166456T3 (da)
GE (1)	GEP20002028B (da)
HR (1)	HRP960313B1 (da)
HU (1)	HU223598B1 (da)
ID (1)	ID16158A (da)
IL (3)	IL122162A (da)
MX (1)	MX9708857A (da)
MY (1)	MY118398A (da)
NO (1)	NO309899B1 (da)
NZ (1)	NZ312906A (da)
PE (1)	PE1798A1 (da)
PL (1)	PL192244B1 (da)
RO (1)	RO120068B1 (da)
SK (1)	SK284201B6 (da)
TW (1)	TW401399B (da)
UA (1)	UA44796C2 (da)
WO (1)	WO1997003958A1 (da)
ZA (1)	ZA966045B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GEP20002029B (en)	1995-07-17	2000-04-10	Warner Lambert Company Us	(54) Crystalline [R-(R,R,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
US6569461B1 (en)	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
IN191236B (da)	1999-05-25	2003-10-11	Ranbaxy Lab Ltd
ES2234699T3 (es) *	1999-11-17	2005-07-01	Teva Pharmaceutical Industries Ltd.	Forma polimorfica de atorvastatina calcio.
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
SI20425A (sl)	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
EP1584616A1 (en) *	1999-12-17	2005-10-12	Pfizer Science and Technology Ireland Limited	Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt
ES2258030T3 (es) *	1999-12-17	2006-08-16	Pfizer Science And Technology Ireland Limited	Procedimiento para producir atorvastatina calcio cristalina.
KR100704213B1 (ko) *	2000-11-03	2007-04-10	테바 파마슈티컬 인더스트리즈 리미티드	아토르바스타틴 헤미-칼슘 ｖｉｉ형
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
RU2344127C2 (ru) *	2000-11-30	2009-01-20	Тева Фамэситикл Индастрис Лтд.	Новые кристаллические структуры (полиморфные модификации) полукальциевой соли аторвастатина и способы получения этих и других полиморфных модификаций соли аторвастатина
LT5196B (lt)	2000-11-30	2005-02-25	Teva Pharmaceutical Industries Ltd.	Naujos atorvastatino pusiau kalcio kristalinės formos ir jų gavimo būdai, taip pat ir nauji kitų formų gavimo būdai
CA2622477A1 (en)	2000-12-27	2002-07-04	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
US6476235B2 (en)	2001-01-09	2002-11-05	Warner-Lambert Company	Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1734034A3 (en)	2001-01-09	2007-01-03	Warner-Lambert Company LLC	Carboxylic acid salts of beta-alanine esters or -amides
WO2002057229A1 (en) *	2001-01-19	2002-07-25	Biocon India Limited	FORM V CRYSTALLINE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl) *	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
BR0210666A (pt)	2001-06-29	2004-10-05	Warner Lambert Co	Formas cristalinas do sal de cálcio do ácido [r-(r,r)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
AU2002255479B2 (en) *	2001-07-30	2008-09-11	Dr. Reddy's Laboratories Ltd.	Crystalline forms VI and VII of atorvastatin clacium
US7074818B2 (en)	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
IL159861A0 (en) *	2001-08-03	2004-06-20	Ciba Sc Holding Ag	Crystalline forms of fluvastatin sodium
US20060020137A1 (en) *	2001-11-29	2006-01-26	Limor Tessler	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) *	2001-12-12	2007-02-15		Crystalline calcium salt of (2:1) [r-(r,r)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs)	2002-02-01	2006-08-16	Zentiva, A.S.	Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CA2475864A1 (en) *	2002-02-15	2003-08-28	Teva Pharmaceutical Industries Ltd.	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
HRP20040767A2 (en) *	2002-02-19	2004-12-31	Teva Pharma	Desolvating solvates of atorvastatin hemi-calcium
RU2309141C2 (ru) *	2002-03-18	2007-10-27	Байокон Лимитид	АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
HUP0500074A3 (en)	2002-03-18	2005-07-28	Biocon Ltd Bangalore	Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
ITMI20020907A1 (it) *	2002-04-29	2003-10-29	Chemi Spa	Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CN100357289C (zh)	2002-08-06	2007-12-26	沃尼尔·朗伯有限责任公司	制备5－(4－氟苯基)－1－[2－((2r,4r)－4－羟基－6－氧代－四氢－吡喃－2－基)乙基]－2－异丙基－4－苯基－1h－吡咯－3－羧酸苯基酰胺的方法
WO2004022053A1 (en) *	2002-09-03	2004-03-18	Morepen Laboratories Limited	Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl) *	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
HRP20020885B1 (en) *	2002-11-11	2007-05-31	GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o.	SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
WO2004050618A2 (en) *	2002-11-28	2004-06-17	Teva Pharmaceutical Industries Ltd.	Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Crystalline form F of Atorvastatin hemi-calcium salt
EP1615883A1 (en) *	2003-04-14	2006-01-18	Warner-Lambert Company	Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US7790197B2 (en) *	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
US7655692B2 (en) *	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
US20040253305A1 (en) *	2003-06-12	2004-12-16	Luner Paul E.	Pharmaceutical compositions of atorvastatin
CN101318923A (zh) *	2003-09-17	2008-12-10	沃尼尔·朗伯有限责任公司	[R－(R,R)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
CN1960972A (zh) *	2004-04-16	2007-05-09	辉瑞产品公司	用于形成无定形阿托伐它汀钙的方法
CA2649054A1 (en) *	2004-05-05	2005-11-10	Pfizer Products Inc.	Salt forms of [r-(r,r)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2573969C (en) *	2004-07-16	2014-02-04	Lek Pharmaceuticals D.D.	Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja)	2004-07-20	2008-03-06	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
US7645888B2 (en)	2004-08-27	2010-01-12	Biocon Limited	Process for the production of amorphous atorvastatin calcium
WO2006037125A1 (en) *	2004-09-28	2006-04-06	Teva Pharmaceutical Industries Ltd.	Process for preparing forms of atorvastatin calcium substantially free of impurities
CN101039906A (zh) *	2004-10-18	2007-09-19	特瓦制药工业有限公司	通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
WO2006046109A1 (en)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Process for forming amorphous atorvastatin
WO2006048894A1 (en) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Novel crystalline forms of atorvastatin calcium and processes for preparing them.
WO2006054308A2 (en)	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Stable atorvastatin formulations
JP2008521878A (ja) *	2004-12-02	2008-06-26	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	非晶質アトルバスタチンの医薬組成物及びその製造のための方法
GB2424880A (en) *	2005-04-06	2006-10-11	Generics	Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
CA2547216A1 (en) *	2005-09-21	2007-03-21	Renuka D. Reddy	Process for annealing amorphous atorvastatin
ATE466840T1 (de)	2005-11-21	2010-05-15	Warner Lambert Co	Neue formen von är-(r,r)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
US8080672B2 (en)	2005-12-13	2011-12-20	Teva Pharmaceutical Industries Ltd.	Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising amorphous atorvastatin
EP1877375A1 (en) *	2006-03-01	2008-01-16	Teva Pharmaceutical Industries Ltd	Process for preparing a crystalline form of atorvastatin hemi-calcium
US20070265456A1 (en) *	2006-05-09	2007-11-15	Judith Aronhime	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100878140B1 (ko) *	2007-01-29	2009-01-12	한미약품 주식회사	아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
WO2009007856A2 (en) *	2007-07-11	2009-01-15	Actavis Group Ptc Ehf	Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
WO2009013633A2 (en) *	2007-07-20	2009-01-29	Actavis Group Ptc Ehf	Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
DE102007052071A1 (de)	2007-10-30	2009-05-07	Stada Arzneimittel Ag	Stabilisiertes Atorvastatin
US20090124817A1 (en) *	2007-11-09	2009-05-14	The Industry & Academic Cooperation In Chungnam National University	Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
US8115015B2 (en) *	2009-01-26	2012-02-14	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs)	2010-01-19	2011-07-27	Zentiva, K. S	Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko)	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN103274985B (zh) *	2010-12-03	2016-03-09	上海科州药物研发有限公司	一种阿托伐他汀氨基酸盐
US9050342B2 (en)	2011-03-29	2015-06-09	Pfizer Inc.	Beneficial effects of combination therapy on cholesterol
US20140335179A1 (en) *	2011-07-01	2014-11-13	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Micronized crystals of atorvastatin hemicalcium
CN103483238B (zh) *	2013-08-20	2014-12-31	蚌埠丰原医药科技发展有限公司	阿托伐他汀钙三水合物的制备方法
CN106432033B (zh) *	2016-10-21	2018-07-27	江苏阿尔法药业有限公司	一种无定形阿托伐他汀钙的制备方法
KR101723783B1 (ko)	2017-02-24	2017-04-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2025147589A1 (en)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE409281C (de) *	1922-04-26	1925-01-31	Farbenfab Vorm Bayer F & Co	Verfahren zur Herstellung von sauren Monoazofarbstoffen fuer Wolle
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) *	1989-09-07	1994-05-31	Karl Folkers Foundation For Biomedical And Clinical Research	Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
JP3254219B2 (ja) *	1993-01-19	2002-02-04	ワーナー−ランバート・コンパニー	安定な経口用のｃｉ−９８１製剤およびその製法

1996
- 1996-07-03 HR HR960313A patent/HRP960313B1/xx not_active IP Right Cessation
- 1996-07-08 CZ CZ1998123A patent/CZ294109B6/cs not_active IP Right Cessation
- 1996-07-08 ES ES96924367T patent/ES2166456T3/es not_active Expired - Lifetime
- 1996-07-08 CN CN96195632A patent/CN1081632C/zh not_active Expired - Lifetime
- 1996-07-08 EE EE9800016A patent/EE03607B1/xx unknown
- 1996-07-08 GE GEAP19964148A patent/GEP20002028B/en unknown
- 1996-07-08 HU HU9901687A patent/HU223598B1/hu active IP Right Grant
- 1996-07-08 JP JP50670997A patent/JP3296563B2/ja not_active Expired - Lifetime
- 1996-07-08 NZ NZ312906A patent/NZ312906A/xx not_active IP Right Cessation
- 1996-07-08 RO RO98-00059A patent/RO120068B1/ro unknown
- 1996-07-08 WO PCT/US1996/011367 patent/WO1997003958A1/en not_active Ceased
- 1996-07-08 CA CA002220458A patent/CA2220458C/en not_active Expired - Lifetime
- 1996-07-08 IL IL12216296A patent/IL122162A/xx not_active IP Right Cessation
- 1996-07-08 KR KR10-1998-0700347A patent/KR100431039B1/ko not_active Expired - Lifetime
- 1996-07-08 DK DK96924367T patent/DK0848704T3/da active
- 1996-07-08 BR BR9610567A patent/BR9610567A/pt not_active Application Discontinuation
- 1996-07-08 MX MX9708857A patent/MX9708857A/es active IP Right Grant
- 1996-07-08 PL PL324532A patent/PL192244B1/pl unknown
- 1996-07-08 EA EA199800129A patent/EA000505B1/ru not_active IP Right Cessation
- 1996-07-08 SK SK59-98A patent/SK284201B6/sk not_active IP Right Cessation
- 1996-07-08 AT AT96924367T patent/ATE207465T1/de not_active IP Right Cessation
- 1996-07-08 AU AU64841/96A patent/AU725368B2/en not_active Expired
- 1996-07-10 TW TW085108326A patent/TW401399B/zh not_active IP Right Cessation
- 1996-07-11 IL IL128863A patent/IL128863A/en not_active IP Right Cessation
- 1996-07-15 ID IDP962021A patent/ID16158A/id unknown
- 1996-07-16 MY MYPI96002920A patent/MY118398A/en unknown
- 1996-07-16 ZA ZA9606045A patent/ZA966045B/xx unknown
- 1996-07-17 PE PE1996000540A patent/PE1798A1/es not_active Application Discontinuation
- 1996-07-17 CO CO96037513A patent/CO4700442A1/es unknown
- 1996-08-07 UA UA98020825A patent/UA44796C2/uk unknown
1998
- 1998-01-14 BG BG102186A patent/BG63629B1/bg unknown
- 1998-01-16 NO NO980208A patent/NO309899B1/no not_active IP Right Cessation
1999
- 1999-07-26 US US09/360,778 patent/US6121461A/en not_active Expired - Lifetime
2006
- 2006-08-08 IL IL177378A patent/IL177378A0/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR19990029044A (ko)	1999-04-15
MY118398A (en)	2004-10-30
KR100431039B1 (ko)	2004-08-25
UA44796C2 (uk)	2002-03-15
EA199800129A1 (ru)	1998-08-27
IL128863A0 (en)	2000-01-31
WO1997003958A1 (en)	1997-02-06
EE9800016A (et)	1998-08-17
JP3296563B2 (ja)	2002-07-02
HUP9901687A2 (hu)	1999-10-28
HK1018053A1 (en)	1999-12-10
HRP960313A2 (en)	1998-04-30
ES2166456T3 (es)	2002-04-16
CN1081632C (zh)	2002-03-27
GEP20002028B (en)	2000-04-10
HU223598B1 (hu)	2004-10-28
BG102186A (en)	1998-10-30
JPH11509229A (ja)	1999-08-17
US6121461A (en)	2000-09-19
EE03607B1 (et)	2002-02-15
HRP960313B1 (en)	2002-08-31
RO120068B1 (ro)	2005-08-30
DK0848704T3 (da)	2002-02-04
AU725368B2 (en)	2000-10-12
CA2220458C (en)	2002-09-24
IL122162A0 (en)	1998-04-05
EA000505B1 (ru)	1999-10-28
SK284201B6 (sk)	2004-10-05
MX9708857A (es)	1998-03-31
CO4700442A1 (es)	1998-12-29
CZ12398A3 (cs)	1998-06-17
ZA966045B (en)	1997-02-04
AU6484196A (en)	1997-02-18
CN1190957A (zh)	1998-08-19
NZ312906A (en)	2000-12-22
IL177378A0 (en)	2006-12-10
PL324532A1 (en)	1998-06-08
IL128863A (en)	2006-09-05
SK5998A3 (en)	1998-05-06
ID16158A (id)	1997-09-11
HUP9901687A3 (en)	2000-04-28
NO309899B1 (no)	2001-04-17
CZ294109B6 (cs)	2004-10-13
CA2220458A1 (en)	1997-02-06
NO980208L (no)	1998-01-16
PL192244B1 (pl)	2006-09-29
PE1798A1 (es)	1998-03-04
BG63629B1 (bg)	2002-07-31
TW401399B (en)	2000-08-11
NO980208D0 (no)	1998-01-16
BR9610567A (pt)	1999-07-06
ATE207465T1 (de)	2001-11-15

Legal Events

Date	Code	Title	Description
2001-07-24	NP	Permission for amending the patent specification granted (section 66, patents law 1967)
2002-02-10	NP	Permission for amending the patent specification granted (section 66, patents law 1967)	Free format text: JOURNAL NO. 4/2001P. 1751, 1752, 1753 NOTICES PATENT APPLICATION NO. 122162, 122161, 122118 DELETE THE ABOVE NOTICES. THE NOTICES WERE PUBLISHED BEFORE PAYMENT OF PUBLICATION FEES. THE NOTICES ARE BEING REPUBLISHED IN THIS JOURNAL.
2004-02-19	NP	Permission for amending the patent specification granted (section 66, patents law 1967)
2006-09-05	FF	Patent granted
2006-10-30	KB	Patent renewed
2010-11-30	KB	Patent renewed
2014-07-31	KB	Patent renewed
2017-02-28	EXP	Patent expired

Publication	Publication Date	Title
IL122162A (en)	1999-07-14	Crystalline form iii atorvastatin and pharmaceutical composition containing it
NZ312907A (en)	2000-12-22	Crystalline [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl
EP3009423A3 (en)	2016-12-28	Crystalline forms of [r-(r,r)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
DK0839132T5 (da)	2006-03-20	Fremgangsmåde til fremstilling af amorft [R-(R,R)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)
CA2521908A1 (en)	2003-01-16	Crystalline forms of [r-(r,r)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
NZ507836A (en)	2001-02-23	Crystalline [r(r ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)